Source comparison
Hexarelin's Dual Mechanisms: GH Release vs Cardiac Protection
Hexarelin binds to two distinct receptor systems. The first is the growth hormone secretagogue receptor (GHS-R1a), which triggers pulsatile GH release from the anterior pituitary. This is the mechanism behind its muscle-building and metabolic applications. The
This comparison does not assign a generated winner or score.
- Hexarelin binds to two distinct receptor systems. The first is the growth hormone secretagogue receptor (GHS-R1a), which triggers pulsatile GH release from the anterior pituitary. This is the mechanism behind its muscle-building and metabolic applications. The second is the CD36 scavenger receptor, highly expressed in cardiac tissue, which mediates direct cardioprotective signaling without involving the hypothalamic-pituitary axis.
- When Hexarelin binds CD36 receptors on cardiomyocyte membranes, it activates ERK1/2 and PI3K/Akt pathways. Both critical for cellular survival during oxidative stress. A 2021 study in Frontiers in Pharmacology demonstrated that CD36 knockout mice lost all cardioprotective benefit from Hexarelin administration, while GH secretion remained intact. This confirmed the pathways are mechanistically independent.
- The optimal dosage for cardiac protection sits below the threshold that maximizes GH release. Doses above 6 mcg/kg trigger robust GH pulses but don't proportionally increase cardioprotective signaling. The CD36 receptors saturate at lower concentrations. Research protocols targeting cardiac outcomes typically use 2–4 mcg/kg, while GH-focused protocols often escalate to 100–200 mcg per dose regardless of body weight.